Erlotinib, vemurafenib, and lapatinib eradicate PC9, A375, and BT474 cell lines through GPX4 inhibition, respectively, indicating the clinical potential of GPX4 inhibitors for dormant cancer therapy [148]. The gene discussed is GPX4; the disease is cancer.